Price movement over the last 24 hours
Abeona Therapeutics Inc vs Dow Jones Industrial Average ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Dow Jones Industrial Average ETF trades at $522.88. Which is the better fit depends on your goals.
| ABEO | DIA | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $530.02 |
52-Week Low | $4.17 | $435.72 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $530.02, up 0.41% with a bullish technical signal from moving averages. The ETF tracks the Dow Jones Industrial Average, which recently surpassed 53,000 for the first time, driven by financials and tech exposure. Recent dividend distributions and strong institutional interest support the positive momentum, though oscillators indicate some overbought conditions with RSI levels above 70.
Outlook remains favorable given the Dow's 8% YTD gain and historical 13.3% average annual returns. Key risks include election-year volatility and potential Fed policy shifts under new Chair Kevin Warsh. Investors benefit from blue-chip diversification, but should monitor technical resistance near $533 and broader market sentiment for sustained upside.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →